Dupilumab: Mechanism of action, clinical, and translational science
Clinical and Translational Science · 2024-08 · 17 (8)
DOI: 10.1111/cts.13899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 30.07.2024. Verfasst von Marc R McCann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin-4 Receptor alpha Subunit, Dermatitis, Atopic, Interleukin-13. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)‐4 receptor alpha subunit (IL‐4Rα) that blocks IL‐4 and IL‐13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
- Sanofi, Bridgewater, New Jersey, USA.
ORCID-Profile: Marc R McCann, Matthew P Kosloski, John D Davis
Zitieren
APA
McCann, M. R., Kosloski, M. P., Xu, C., Davis, J. D., & Kamal, M. A. (2024). Dupilumab: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.13899
Vancouver
McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.13899
BibTeX
@article{McCann2024,
author = {McCann, Marc R and Kosloski, Matthew P and Xu, Christine and Davis, John D and Kamal, Mohamed A},
title = {Dupilumab: Mechanism of action, clinical, and translational science},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {8},
doi = {10.1111/cts.13899}
}
EUVIMED